Eagle Claw Capital Managment, LLC Gilead Sciences, Inc. Transaction History
Eagle Claw Capital Managment, LLC
- $538 Million
- Q1 2024
A detailed history of Eagle Claw Capital Managment, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Eagle Claw Capital Managment, LLC holds 8,735 shares of GILD stock, worth $597,474. This represents 0.12% of its overall portfolio holdings.
Number of Shares
8,735
Previous 9,225
5.31%
Holding current value
$597,474
Previous $747,000
14.46%
% of portfolio
0.12%
Previous 0.16%
Shares
28 transactions
Others Institutions Holding GILD
# of Institutions
1,885Shares Held
1BCall Options Held
8.71MPut Options Held
8.02M-
Black Rock Inc. New York, NY123MShares$8.38 Billion0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$7.85 Billion0.17% of portfolio
-
Capital World Investors Los Angeles, CA84.5MShares$5.78 Billion1.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.2MShares$4.19 Billion1.05% of portfolio
-
State Street Corp Boston, MA57.7MShares$3.95 Billion0.19% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $85.7B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...